IR@PKUHSC  > 北京大学第一临床医学院
学科主题临床医学
Biphasic insulin aspart 30 as insulin initiation or replacement therapy: the China cohort of the IMPROVE study
Yang, Wenying1; Gao, Yan2; Liu, Guoliang3; Chen, Lulu4; Fu, Zuzhi5; Zou, Dajin6; Feng, Ping7; Zhao, Zhigang8
关键词BIAsp 30 China Observational study Routine practice
刊名CURRENT MEDICAL RESEARCH AND OPINION
2010
DOI10.1185/03007990903364640
26期:1页:101-107
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Medicine, General & Internal ; Medicine, Research & Experimental
研究领域[WOS]General & Internal Medicine ; Research & Experimental Medicine
关键词[WOS]DIABETIC-PATIENTS ; TYPE-2 ; RISK ; PREVALENCE
英文摘要

Aims: To explore safety and efficacy of BIAsp 30 as initiation or replacement therapy in routine clinical practice in patients with poorly controlled diabetes in the Chinese cohort of the IMPROVE study.

Methods: In the 26-week, non-interventional, observational study, Chinese subjects with diabetes started BIAsp 30 treatment in routine care. Data from patients′ diaries and medical records were transferred to CRFs by participating physicians.

Clinical trial registration: NCT00659282.

Results: Of the 21,729 subjects enrolled (mean age 54.0 years, BMI 24.6 kg/m(2), diabetes duration 4.86 years), 32.3% were treatment-naive, 59.3% were from oral anti-diabetic drugs (OADs) only and 8.1% were from insulin +/- OADs. Overall, mean HbA(1c) and FBG decreased by 2.82% and 5 mmol/L, respectively. In the subgroups, changes were: -3.27% and -6.06 mmol/L (treatment-naive), -2.57% and -4.54 mmol/L (OADs only), -2.96% and 3.51 mmol/L (insulin +/- OADs) all p < 0.05. HbA(1c)< 7% was achieved by 71.4% of patients. Only 0.1% of subjects reported major hypoglycaemia and 73 SADRs were observed without significant difference compared to those at baseline. Body weight did not change significantly.

Conclusions: Regardless of previous treatments, insulin initiation or replacement with BIAsp 30 improved glycaemic control without increasing major hypoglycaemia or weight gain in Chinese patients with diabetes.

语种英语
WOS记录号WOS:000273417900012
资助机构Novo Nordisk
引用统计
被引频次:6[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/65120
专题北京大学第一临床医学院
作者单位1.China Japan Friendship Hosp, Dept Endocrinol, Beijing, Peoples R China
2.Huazhong Technol Univ, Union Hosp, Wuhan, Peoples R China
3.Sun Yat Sen Univ, Affiliated Hosp 2, Guangzhou 510275, Guangdong, Peoples R China
4.Second Mil Med Univ, Changhai Hosp, Shanghai, Peoples R China
5.Peking Univ, Affiliated Hosp 1, Beijing 100871, Peoples R China
6.China Med Univ, Affiliated Hosp 1, Shenyang, Peoples R China
7.Tianjin Med Univ, Gen Hosp, Tianjin, Peoples R China
8.Henan Prov Peoples Hosp, Zhengzhou, Henan, Peoples R China
推荐引用方式
GB/T 7714
Yang, Wenying,Gao, Yan,Liu, Guoliang,et al. Biphasic insulin aspart 30 as insulin initiation or replacement therapy: the China cohort of the IMPROVE study[J]. CURRENT MEDICAL RESEARCH AND OPINION,2010,26(1):101-107.
APA Yang, Wenying.,Gao, Yan.,Liu, Guoliang.,Chen, Lulu.,Fu, Zuzhi.,...&Zhao, Zhigang.(2010).Biphasic insulin aspart 30 as insulin initiation or replacement therapy: the China cohort of the IMPROVE study.CURRENT MEDICAL RESEARCH AND OPINION,26(1),101-107.
MLA Yang, Wenying,et al."Biphasic insulin aspart 30 as insulin initiation or replacement therapy: the China cohort of the IMPROVE study".CURRENT MEDICAL RESEARCH AND OPINION 26.1(2010):101-107.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Yang, Wenying]的文章
[Gao, Yan]的文章
[Liu, Guoliang]的文章
百度学术
百度学术中相似的文章
[Yang, Wenying]的文章
[Gao, Yan]的文章
[Liu, Guoliang]的文章
必应学术
必应学术中相似的文章
[Yang, Wenying]的文章
[Gao, Yan]的文章
[Liu, Guoliang]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。